Dr. James H. Doroshow has been the Director of Division of Cancer Treatment and Diagnosis,
National Cancer Institute, since 2004. From 1983 to 2004, Dr. Doroshow was the Chairman of the City of Hope
Comprehensive Cancer Center's Department of Medical Oncology and Therapeutics Research. From the time of his
first research grant in 1980, Dr. Doroshow was continuously funded by NCI until he moved to the NIH in 2004.
He is the author of over 300 full-length publications in the areas of anthracycline antibiotic molecular pharmacology,
the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors.
Dr. Doroshow served from 1995-2001 as a member of the Subspecialty Board on Medical Oncology of the American
Board of Internal Medicine, and from 1999-2000 as Chair of NCI's Scientific Review Group A-Cancer Centers.
He is currently a member of the FDA's Oncologic Drugs Advisory Committee.
Dr. Doroshow received his bachelor's degree, magna cum laude, from Harvard College in 1969 and his medical degree from Harvard Medical School in 1973. After completing an internship and residency in Internal Medicine at the Massachusetts General Hospital in Boston, he spent three years (1975-78) performing his fellowship in Medical Oncology on the Medicine and Clinical Pharmacology Branches of the NCI.
View Dr. Doroshow's Current Clinical Trials
Our laboratory focuses on the role of oxidant-mediated signalling in growth factor- and drug-related inhibition of tumor cell proliferation. We are particularly interested in the epithelial NADPH oxidase gene family and the development of novel small molecular inhibitors of these proteins.
This page was last updated on 6/11/2008.